This approach allowed us to obtain, in a quick and cost-effective manner, one compound (named here P1.3) that has the capacity to efficiently inhibit the interaction of RAS with its effectors in cells in vitro and inhibits survival of pancreatic tumour cells expressing oncogenic KRAS. Here, KRAS is linked to pancreatic neoplasm.